Los Angeles Capital Management LLC Takes Position in Altimmune, Inc. $ALT

Los Angeles Capital Management LLC acquired a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,947 shares of the company’s stock, valued at approximately $54,000.

Several other institutional investors have also recently added to or reduced their stakes in ALT. Bank of New York Mellon Corp boosted its stake in shares of Altimmune by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock worth $945,000 after purchasing an additional 2,162 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after buying an additional 2,241 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of Altimmune by 20.3% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $67,000 after acquiring an additional 2,268 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Altimmune by 5.4% during the 1st quarter. MetLife Investment Management LLC now owns 46,870 shares of the company’s stock worth $234,000 after acquiring an additional 2,396 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Altimmune by 3.9% in the first quarter. Deutsche Bank AG now owns 79,851 shares of the company’s stock worth $399,000 after acquiring an additional 3,026 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 11.0%

ALT opened at $4.65 on Wednesday. The firm’s 50 day moving average is $3.95 and its 200-day moving average is $4.48. The firm has a market capitalization of $485.19 million, a P/E ratio of -3.94 and a beta of 0.01. Altimmune, Inc. has a 52-week low of $2.90 and a 52-week high of $10.88. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. Analysts expect that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALT has been the subject of several research analyst reports. B. Riley dropped their price target on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Altimmune in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. Wall Street Zen raised shares of Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.